Brief: Eiger Biopharmaceuticals And Amylyx Entered Into An Asset Purchase Agreement
21/06/2024 21:36
June 21 (Reuters) - Eiger Biopharmaceuticals Inc:
* COMPANY AND AMYLYX ENTERED INTO AN ASSET PURCHASE
AGREEMENT
* AMYLYX AGREED TO BUY ALL OF CO'S RIGHTS, TITLE,INTERESTS
IN
ASSETS,INTERESTS USED IN DEVELOPMENT,
MANUFACTURE,COMMERCIALIZATION OF AVEXITIDE
* ASSET PURCHASE AGREEMENT FOR $35.1 MILLION, PLUS AGGREGATE
AMOUNT OF DETERMINED CURE COSTS AND ASSUMED LIABILITIES
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eiger Biopharmaceuticals
See all newsBrief: Eiger Biopharmaceuticals On Sept 5, Bankruptcy Court Entered Order Confirming Fifth Amended Joint Plan Of Liquidation Of Co & Its Debtor Affiliates
Amylyx to buy bankrupt Eiger's experimental drug to treat low blood sugar
Brief: Eiger Biopharmaceuticals And Amylyx Entered Into An Asset Purchase Agreement
Eiger BioPharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Eiger BioPharmaceuticals Inc expected to post a loss of $7.50 a share - Earnings Preview